FDA advisory committee to discuss OTC cough/ cold products in children under six
The FDA is asking for advice from its advisory committees about the use of cough and cold products in children under six years of age. The agency reviews pertain to both single-ingredient products and products that include multiple combinations of ingredients. The FDA is making the background briefing information available for the Oct. 18 and 19 Nonprescription Drugs and Pediatric Advisory Committees joint meeting at www.fda.gov/cder/drug/advisory/cough_cold.htm.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
FDA Approves Aprocitentan For Treatment of Uncontrolled High Blood Pressure
March 20th 2024Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.